| 5 mins | 30 mins | Hourly | Daily | Weekly |
|---|---|---|---|---|
| SELL | SELL | SELL | SELL | SELL |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MA5 | 1.29▼ | 1.30▼ | 1.30▼ | 1.29▼ | 1.36▼ |
| MA10 | 1.31▼ | 1.32▼ | 1.31▼ | 1.26▲ | 1.61▼ |
| MA20 | 1.31▼ | 1.30▼ | 1.30▼ | 1.41▼ | 1.88▼ |
| MA50 | 1.30▼ | 1.27▲ | 1.26▲ | 1.70▼ | 2.71▼ |
| MA100 | 1.25▲ | 1.30▼ | 1.36▼ | 1.94▼ | 5.37▼ |
| MA200 | 1.33▼ | 1.49▼ | 1.62▼ | 2.58▼ | 10.09▼ |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MACD | -0.007▼ | -0.006▼ | -0.004▼ | 0.013▲ | -0.005▼ |
| RSI | 43.311▼ | 45.779▼ | 48.107▼ | 37.973▼ | 30.411▼ |
| STOCH | 3.846▼ | 36.138 | 42.708 | 30.243 | 7.844▼ |
| WILL %R | -100.000▼ | -87.500▼ | -87.500▼ | -75.316▼ | -83.043▼ |
| CCI | -99.690 | -79.232 | -61.272 | -9.064 | -132.518▼ |
|
Thursday, July 10, 2025 05:19 AM
SNGX READ THE FULL SNGX RESEARCH REPORT Business Update Multiple Catalysts Ahead in 2H25 Soligenix, Inc. (NASDAQ:SNGX) is a late-stage biopharmaceutical company developing products to treat rare ...
|
|
Wednesday, July 09, 2025 12:16 PM
Soligenix (NASDAQ: SNGX) , a late-stage biopharmaceutical company developing therapies for rare diseases with unmet medical needs, issued a sharehold ...
|
|
Tuesday, July 08, 2025 04:29 AM
Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet ...
|
| date | open | high | low | close | volume |
|---|---|---|---|---|---|
| 15/07/25 | 1.30 | 1.305 | 1.285 | 1.285 | 129,206 |
| 14/07/25 | 1.28 | 1.38 | 1.25 | 1.36 | 260,917 |
| 11/07/25 | 1.27 | 1.3001 | 1.2382 | 1.27 | 124,338 |
| 10/07/25 | 1.25 | 1.39 | 1.25 | 1.27 | 570,100 |
| 09/07/25 | 1.23 | 1.30 | 1.20 | 1.25 | 219,273 |
| 08/07/25 | 1.12 | 1.29 | 1.09 | 1.22 | 344,562 |
| 07/07/25 | 1.19 | 1.20 | 1.11 | 1.12 | 383,217 |
| 03/07/25 | 1.20 | 1.25 | 1.20 | 1.20 | 291,008 |
| 02/07/25 | 1.24 | 1.33 | 1.20 | 1.26 | 963,753 |
| 01/07/25 | 1.50 | 1.88 | 1.31 | 1.41 | 48,438,068 |
|
|
||||
|
|
||||
|
|